CANAAN X L.P. 4
4 · NextCure, Inc. · Filed May 13, 2019
Insider Transaction Report
Form 4
NextCure, Inc.NXTC
CANAAN X L.P.
10% Owner
Transactions
- Conversion
Common Stock
2019-05-13+743,110→ 1,188,976 total - Conversion
Series A-2 Preferred Stock
2019-05-13−5,970,000→ 0 total→ Common Stock (743,110 underlying) - Conversion
Series B-1 Preferred Stock
2019-05-13−2,296,605→ 0 total→ Common Stock (285,867 underlying) - Conversion
Common Stock
2019-05-13+729,599→ 1,918,575 total - Purchase
Common Stock
2019-05-13$15.00/sh+50,000$750,000→ 2,254,442 total - Conversion
Series A-3 Preferred Stock
2019-05-13−5,861,455→ 0 total→ Common Stock (729,599 underlying) - Conversion
Common Stock
2019-05-13+445,866→ 445,866 total - Conversion
Series A-1 Preferred Stock
2019-05-13−3,582,000→ 0 total→ Common Stock (445,866 underlying) - Conversion
Common Stock
2019-05-13+285,867→ 2,204,442 total
Footnotes (2)
- [F1]The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date.
- [F2]The shares are held directly by Canaan X L.P. (the "Canaan Fund"). The sole general partner of the Canaan Fund is Canaan Partners X LLC ("Canaan X"), and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund. Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan X, collectively. Canaan X disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any.